In addition to the impacts on normalizing vessel structure and function, targeting metabolism may have further benefits when combined with ICB therapies, such as reduced PD-L1 expression by tumor cells and endothelial cells when targeting glycolysis [86, 87]. Here, CD274 is linked to neoplasm.